The Bethesda System for Reporting Thyroid Cytopathology: Updates from the New 3rd Edition

 

Paul VanderLaan, MD, PhD
Director of Cytopathology
Beth Israel Deaconess Medical Center
Associate Professor of Pathology
Harvard Medical School
Boston, Massachusetts

 

The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) is the most frequently used cytology reporting system for thyroid FNAs worldwide, with the new updated 3rd edition set to be published in the summer of 2023. The new edition will reflect state-of-the-art practice based on published studies since the 2nd edition, as reviewed by an expanded author list including experts from around the globe. New chapters in this edition will cover Clinical Perspectives and Imaging Studies, as well as Molecular and Ancillary Testing. This session will provide an overview of the relevant revisions and updates for the cytology community.

Target Audience

This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.

Learning Objectives

  • Describe the updated implied risk of malignancy/neoplasia for each diagnostic category based on the published literature
  • Appreciate the evolving roles that imaging and ancillary molecular testing has in conjunction with FNA results in the management of thyroid nodules
  • Decide when to best utilize indeterminate diagnostic categories, based on defined cytologic criteria
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 1.00 California Credits
  • 2.00 CMLE
  • 2.00 Florida Credits
  • 2.00 MOC II
  • 2.00 Participant
Course opens: 
01/24/2023
Course expires: 
01/23/2026
Cost:
$105.00

Presenter(s):
Paul VanderLaan, MD, PhD

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.

The following individuals have reported financial relationships:
Oscar Lin MD PhD: Consultant – Hologic and Jansen
Liron Pantanowitz MD: Consultant – Hamamatsu, Advisory Board for Ibex
Martha B Pitman MD FIAC: Consultant – Adenocyte, LLC
Donna K. Russell MEd CT(ASCP) HT(ASCP): Advisory Board – Hologic Scientific
Christopher J. VandenBussche MD PhD: Ad hoc advisory board panel and Consultant – Roche
Paul VanderLaan, MD, PhD: Consultant - Gala Therapeutics, Galvanize Therapeutics

The following individuals have reported no relevant financial relationships:
Susan A. Alperstein, MS, CT(ASCP), Donna Armyalagos, BA, CT(ASCP), Cheryl K. Arnott, SCT(ASCP), Kristen A. Atkins, MD, Khalid Amin, MD, Guliz A. Barkan, MD, Christine N. Booth, MD, Barbara A. Centeno, MD, Bonnie Choy, MD, Deborah J. Chute, MD, Amy C. Clayton, MD, Jacqueline M. Cuda, BS, SCT(ASCP), Kara L. Hansing, MEd, SCT(ASCP)CM, Elizabeth M. Jacobi, MD, Jennifer B. Kernodle-Zimmer, BS, SCT(ASCP), Sara E. Monaco, MD, Caleigh-Shea Murphy, Gabriela M. Oprea-Ilies, MD, Maria Luisa C. Policarpio-Nicolas, MD, Sinchita Roy-Chowdhuri, MD, PhD, Momin T. Siddiqui, MD, FIAC, Jose Victor Scarpa Carniello, MD, Sheila Segura, MD, Paul N. Staats, MD

The ASC staff associated with the development of content for this activity reported no relevant financial relationships.

ACCREDITATION AND DESIGNATION STATEMENTS

Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

American Board of Pathology Maintenance of Certification (CC)
This product can help fulfill the CME requirements mandated by the American Board of Pathology Continuing Certification (CC) process.  Earn up to 2.0 Credit Hours.

Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians.  The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the State of Florida and 1 in the State of California. The credit on each link is good for three years from the live presentation date.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 1.00 California Credits
  • 2.00 CMLE
  • 2.00 Florida Credits
  • 2.00 MOC II
  • 2.00 Participant

Price

Cost:
$105.00
Please login or register to take this course.